Neuroprotective Sirtuin ratio reversed by ApoE4 - sprookjes - yvandenbroek - TriplyDB

Neuroprotective Sirtuin ratio reversed by ApoE4

Neuroprotective Sirtuin ratio reversed by ApoE4

http://www.wikidata.org/entity/Q28300666

about

Polyphenol Stilbenes: Molecular Mechanisms of Defence against Oxidative Stress and Aging-Related Diseases Dynamic self-guiding analysis of Alzheimer's disease.The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model.Apolipoprotein E and Sex Bias in Cerebrovascular Aging of Men and Mice.Functional genetic variants within the SIRT2 gene promoter in acute myocardial infarction.Multifaceted Roles of Metzincins in CNS Physiology and Pathology: From Synaptic Plasticity and Cognition to Neurodegenerative Disorders Reversal of cognitive decline: a novel therapeutic program SIRT1 in the brain-connections with aging-associated disorders and lifespan Metabolic profiling distinguishes three subtypes of Alzheimer's disease.The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer's disease of humans and mice Direct Transcriptional Effects of Apolipoprotein E Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on ω-3 supplementation.Role of Apolipoproteins and α-Synuclein in Parkinson's Disease.Inhibition of Poly(ADP-ribose) Polymerase-1 Enhances Gene Expression of Selected Sirtuins and APP Cleaving Enzymes in Amyloid Beta Cytotoxicity.Caloric restriction: beneficial effects on brain aging and Alzheimer's disease.Modulation of innate immunity of patients with Alzheimer's disease by omega-3 fatty acids.Sirtuin 2 Inhibition Improves Cognitive Performance and Acts on Amyloid-β Protein Precursor Processing in Two Alzheimer's Disease Mouse Models.Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment.Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease.Exercise and BDNF reduce Aβ production by enhancing α-secretase processing of APP.Role of prostacyclin signaling in endothelial production of soluble amyloid precursor protein-α in cerebral microvessels.Into the Fourth Dimension: Dysregulation of Genome Architecture in Aging and Alzheimer's Disease.

P2860

Q26800956-427C2CB5-4244-4BA8-8BEE-AECFC3AA74B8 Q28080897-C2AD0E94-4A66-475D-9F23-427FE2096AF6 Q30577199-C4EE7574-A8A4-4429-97FB-542E21D494F3 Q31122715-2481B86A-F919-423B-9A11-C79AAC154255 Q33605950-FD5E8CC0-CF51-4D74-A611-8733CFED0935 Q33854483-23D354EB-3660-4293-9AAF-D9D7085D5DB5 Q34461143-0C527602-2AB7-46CB-86CD-EDD9CC7A8CF0 Q35158382-9BB7A69F-35BA-4815-BD2D-374581B6373C Q36100673-B1BB511D-7206-4BC3-B189-602A20DE0439 Q36393038-8DF4CCFF-1B06-4AF7-BB83-9364BC417668 Q36480230-9644D83C-A1AC-410E-B841-8651D46F2286 Q37510384-9DBF5D76-26E1-42D1-B453-466A6839A02E Q38659590-B6C11CCA-4D26-4A7E-BFEB-E989B39CBA88 Q38683142-B4218288-E7EF-41B3-B2D7-24AD70BA5BF5 Q38848268-4ED86AF5-5AF7-41DA-A856-203BD708EC5A Q39249384-F5A7905D-87FA-4ACE-B72B-11B269E46D0C Q39636393-F4173519-F8FD-4E4E-A246-EA5646CA412B Q47831348-CC9CDB1F-C4F4-4DCD-A711-14AC69F6CD59 Q47844521-CF68CDA4-F4AC-4629-A7B7-397614D18094 Q48313645-B33F98AC-7195-4EAA-A807-F00E12937A8B Q49157255-1A934BCC-415B-4078-83A9-9A71A1A9C0C2 Q51763074-F8DD1FA4-1A60-45F9-A4ED-0C49D5D423AF

P2860

Neuroprotective Sirtuin ratio reversed by ApoE4

http://www.wikidata.org/entity/Q28300666

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Neuroprotective Sirtuin ratio reversed by ApoE4

@ast

Neuroprotective Sirtuin ratio reversed by ApoE4

@en

Neuroprotective Sirtuin ratio reversed by ApoE4

@nl

type

label

Neuroprotective Sirtuin ratio reversed by ApoE4

@ast

Neuroprotective Sirtuin ratio reversed by ApoE4

@en

Neuroprotective Sirtuin ratio reversed by ApoE4

@nl

prefLabel

Neuroprotective Sirtuin ratio reversed by ApoE4

@ast

Neuroprotective Sirtuin ratio reversed by ApoE4

@en

Neuroprotective Sirtuin ratio reversed by ApoE4

@nl

P1433

Q28300666-96428BC5-3DDF-43DF-9B62-8AFD63D25F95

P1476

Q28300666-BE7C8DF8-FC49-428E-9249-94DF6AE3A3B8

P2093

Q28300666-0295DA02-2C35-41F9-843A-E2DAA156E251

Q28300666-0EE2A696-E005-48E6-8935-C8A0F31D7CD0

Q28300666-3590266F-5D68-4018-8A13-0DF6310F75BC

Q28300666-45043A11-8AAE-4739-A5EA-190FE0DED7CE

Q28300666-4F9623D9-D615-4F15-9951-55DADDA14CC8

Q28300666-68D48EBD-859D-440D-AF30-6AFB37929320

Q28300666-7B6B81AD-33A5-46B4-B49F-4D434FE66853

Q28300666-7E61715E-0E73-4C7D-9602-53EEBA189A17

Q28300666-874BDD73-53F0-4366-BAFE-000ACA90F265

Q28300666-E0E567B8-209B-44EC-81CF-2686C040DF6F

P2860

Q28300666-0ADC56CC-18B8-45F7-94D4-758708FD9139

Q28300666-1EC1C40D-CCB1-4993-8049-CB5FACD49103

Q28300666-2347A151-2EFF-43C2-9084-D1BC4B57F422

Q28300666-2D89FF32-9978-4F70-9384-3DF53E987B92

Q28300666-2FC22BA3-C924-4B95-B1F6-DFBACBE0AB50

Q28300666-2FC61EA5-A77D-411D-A185-A84A4072586A

Q28300666-304499F8-4797-4DDF-B257-9B41AA730BA6

Q28300666-481B294B-A034-479C-BFCF-2A85658C5D4A

Q28300666-485F1A4E-C447-497E-82FE-E26A963C5C98

Q28300666-4BC832EF-86B7-4169-9879-D8599EF8E85D

P304

Q28300666-74378499-849E-4D14-903A-89F91E55E786

P31

Q28300666-74D5CB7E-F2DE-4B44-AD59-061F34066CAD

P356

Q28300666-DDD23CBE-EB43-4962-8C30-6E80B1E18A93

P407

Q28300666-96749745-9A0F-4B38-9F87-E51B186B9DA4

P433

Q28300666-B4D463FC-E0C1-446F-BB55-C67AF04222D5

P478

Q28300666-8F7CF3DE-3822-4F9D-9570-BDD3146F08BC

P50

Q28300666-EACC9CEB-1B60-4CF4-B394-0D3385906221

P577

Q28300666-6297D3E6-60AF-40CE-B483-E95A9AC8AC5D

P698

Q28300666-D73B78F2-82EC-4B2F-B4A6-9EBEC264736A

P932

Q28300666-D3F10CA7-572A-40C6-8AA1-9DAC322A7963

P356

PNAS.1314145110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Neuroprotective Sirtuin ratio reversed by ApoE4

@en

P2093

Alexander Patent

http://www.w3.org/2001/XMLSchema#string

Brittany Philpot

http://www.w3.org/2001/XMLSchema#string

Clare A Peters Libeu

http://www.w3.org/2001/XMLSchema#string

Dale E Bredesen

http://www.w3.org/2001/XMLSchema#string

Gabriellee Cailing

http://www.w3.org/2001/XMLSchema#string

Karen S Poksay

http://www.w3.org/2001/XMLSchema#string

Matthew Hart

http://www.w3.org/2001/XMLSchema#string

Olivier Descamps

http://www.w3.org/2001/XMLSchema#string

Rammohan V Rao

http://www.w3.org/2001/XMLSchema#string

Sonia Flores

http://www.w3.org/2001/XMLSchema#string

P2860

Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependence

Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease

The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?

Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease

Evolution in health and medicine Sackler colloquium: Evolution of the human lifespan and diseases of aging: roles of infection, inflammation, and nutrition

Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease.

Acetylation of tau inhibits its degradation and contributes to tauopathy

Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration

Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target.

Altering APP proteolysis: increasing sAPPalpha production by targeting dimerization of the APP ectodomain

P304

18303-18308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1314145110

http://www.w3.org/2001/XMLSchema#string

P407

P433

45

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24145446

http://www.w3.org/2001/XMLSchema#string

P932

3831497

http://www.w3.org/2001/XMLSchema#string